7 studies found for:    Open Studies | "Parotid Diseases"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Evaluation of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Parotidectomy Surgery
Condition: Parotid Diseases
Intervention: Procedure: Parotidectomy
2 Not yet recruiting Feasibility Study of MRI Imaging on Parotid Gland Stimulation
Condition: Parotid Neoplasms
Interventions: Device: MRI;   Other: Citric acid;   Other: Gadovist
3 Unknown  Diagnostic Accuracy of Fine Needle Aspiration in Parotid Tumors
Condition: Parotid Gland Neoplasms
Intervention: Procedure: aspiration biopsy
4 Unknown  Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
Conditions: Measles;   Mumps;   Rubella
Intervention: Biological: MMR Vaccine
5 Recruiting Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors
Conditions: Head and Neck Cancer;   Ototoxicity;   Radiation Toxicity
Interventions: Procedure: adjuvant therapy;   Procedure: assessment of therapy complications;   Procedure: quality-of-life assessment;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
6 Recruiting Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.
Conditions: Measles;   Mumps;   Rubella;   Varicella
Interventions: Biological: MMR  Bio-Manguinhos;   Biological: MMR GlaxoSmithKline
7 Recruiting Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
Condition: Measles; Mumps; Rubella
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762);   Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)

Indicates status has not been verified in more than two years